Purpose The Xavones apigenin and tricin, which occur in leafy vegetables and rice bran, respectively, possess cancer chemopreventive properties in preclinical rodent models. Their pharmacology is only poorly understood. We compared their tissue levels in mice in vivo and their metabolism in liver fractions in vitro. Methods Mice received apigenin or tricin (0.2%) with their diet for 5-7 days, and Xavone levels were compared in the plasma, liver and gastrointestinal mucosa using HPLC-UV. Flavone metabolism was investigated in murine and human liver microsomes or cytosol in vitro co-incubated with uridine 5Ј-diphosphoglucuronic acid or 3Ј-phosphoadenosine-5Ј phosphosulfate. Flavone metabolites were characterized by on-line HPLCmass spectrometry. Results After dietary administration of Xavones for 7 days, levels of tricin in plasma, liver and mucosa exceeded those of apigenin by 350, 33 and 100%, respectively. Apigenin was more rapidly glucuronidated than tricin in liver microsomes, whilst tricin underwent swifter sulfonation than apigenin in liver cytosol. For either Xavone the rate of glucuronidation was much faster than that of sulfonation. Flavone monoglucuronides and monosulfates were identiWed as metabolites in microsomal and cytosolic incubations, respectively.
Introduction
Epidemiological studies suggest that the consumption of fruits and vegetables is associated with a decreased risk of colorectal cancer [1] . Several naturally occurring Xavonoids contained in fruits and vegetables share cancer chemopreventive properties and mechanisms with non-steroidal anti-inXammatory drugs, but may lack their unfavorable safety proWles [2] . Therefore, Xavonoids are promising targets of chemoprevention agent discovery activities. This is particularly apposite in the light of the fact that there are over 4,000 Xavonoids in the plant kingdom, of which only a handful have hitherto been thoroughly investigated for cancer chemopreventive properties, notably quercetin contained in onions and genistein from soya. In plants Xavonoids occur almost exclusively as glycosides, which generate their respective aglycones on hydrolysis caused either at preparation of the foodstuVs for consumption or by intestinal enzymes and/or the intestinal microXora. Tricin (4Ј,5,7-trihydroxy-3Ј,5Ј-dimethoxyXavone, for structure see Fig. 1 ), which occurs in rice bran and other grass species, and its closely related cogener apigenin (4Ј,5,7-trihydroxyXavone, see Fig. 1 ) from leafy vegetables were recently shown to interfere eVectively with prostaglandin generation in human colorectal cells [3] . This paper suggests that the two Xavones exert an eVect on prostaglandin production via diVerential mechanisms, tricin by inhibition of cyclooxygenase (COX) enzyme activity, and apigenin by downregulation of COX-2 expression. Tricin interfered with carcinogenesis in Apc Min mice [4] and C3(1)/SV40 T/t-antigen transgenic ("TAg") mice (H. Cai, W.P. Steward and A.J. Gescher, unpublished data), genetic models of human carcinogenesis, the former of gastrointestinal origin characterized by an Apc gene mutation, the latter of mammary origin associated with dysfunctional Rb and p53 tumor suppressors. Apigenin remains to be tested in these models. In general, Xavonoids are characterized by poor systemic availability. The rational selection of Xavonoid analogues for advancement into clinical development requires robust knowledge of not only their preclinical eYcacy and biochemical mechanisms, but also bioavailability and metabolism. In order to explore the potential suitability of tricin and/ or apigenin for clinical development, we compared their availability in blood, liver and gut mucosa in mice after dietary ingestion, and their metabolism in murine and human hepatic and gut fractions in vitro. Mice received either Xavone with their diet, and Xavone levels were measured by HPLC with UV detection. Their metabolism was compared in vitro in murine and human liver and gut preparations fortiWed with suitable cofactors and analyzed by HPLC with UV or mass spectrometric detection.
Materials and methods

Chemicals
Apigenin was purchased from Apin Chemicals Ltd. (Abingdon, UK). Tricin was custom-synthesized for the US NCI Division of Cancer Prevention by Syncom (Groningen, the Netherlands). Both Xavones were >99% pure as determined by HPLC analysis. Uridine 5Ј-diphosphoglucuronic acid (UDPGA), 3Ј-phosphoadenosine-5Ј phosphosulfate (PAPS), nicotinamide adenine dinucleotide 2Ј-phosphate (NADPH), quercetin and reagents for HPLC analysis (all of Analytic Reagent grade) were obtained from Sigma Chemical Comp (Poole, UK). HPLC-grade methanol was purchased from Fisher Chemicals (Loughborough, UK), and water was puriWed in a laboratory Nano-Pure water puriWcation system (Barnstead, UK).
Animals and treatments
C57BL/6J mice (aged 6-8 weeks), the background strain of the Apc Min mouse, were purchased from Harlan (Oxon, UK). Mice were housed under sterile conditions in a room maintained at 22°C with a 12 h light/ dark cycle. Experiments were carried out under animal project license PPL 40/2496, granted to Leicester University by the UK Home OYce. The experimental design was vetted by the Leicester University Local Ethical Committee for Animal Experimentation and met the standards required by the United Kingdom Coordinating Committee on Cancer Research [5] . Mice (4-10 per group) received AIN 93G diet or AIN diet containing 0.2% Xavone (dose: 300 mg/ kg = 0.9 mmol/kg tricin or 1.1 mmol/kg apigenin). Dietary administration is customarily used in rodent intervention studies. The choice of dose was based on the fact that tricin at this dose reduced adenoma multiplicity in the Apc Min mouse [4] . After 5, 6 or 7 days, mice were killed by cardiac exsanguinations under terminal anaesthesia (halothane), and blood was collected. In animals exposed to Xavones for 7 days liver and gastrointestinal tract were also obtained. Plasma was obtained after centrifugation at 13,000£g (20 min, 4°C). The intestinal tract was Xushed with phosphatebuVered saline (10 ml) to remove contents. Then it was cut open and tissue epithelial scrapings were collected by gently brushing the epithelial layer with a metal spatula. Liver and intestinal mucosa tissues were snapfrozen in liquid nitrogen. Tissues and plasma were kept at ¡80°C until analysis, for not longer than 4 weeks, conditions under which we had established that Xavones in plasma are completely stable.
Tissue sample preparation
Plasma and tissues were thawed at room temperature. Tissues were mixed with an equal volume of isotonic potassium chloride solution and homogenized (Ystral X 10/20 homogeniser, Ballrechten-Dottingen, Germany). An aliquot of plasma or tissue homogenate was added to two volumes of 0.1 M acetic acid in acetone. 
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The mix was vortexed (2 £ 1 min) and centrifuged (13,000£g, 20 min Flavone analysis by HPLC Analysis of tricin and apigenin in plasma, tissues and in incubation mixtures with liver or gut fractions was performed using a reversed phase HPLC method described previously [7] [8] [9] . Two systems were used: (1) a Varian ProStar 230 pump, a ProStar 410 autosampler and a ProStar 325 UV-visible or ProStar 320 photodiode array detector (Varian Inc, Oxford, UK), or (2) an Acquity UPLC system (Waters Corp. Milford, USA) with TUV detector and sample and binary solvent manager. UV detection was at 355 or 336 nm, the maximum absorbance wavelengths of tricin and apigenin, respectively. Separation was achieved on either a Hypersil BDS C 18 column (250 £ 4.6 mm, particle size 5 m, Thermo Electron Corp., Runcorn, UK) in the case of the Varian system, or an Acquity UPLC BEH C 18 column (50 £ 2.1 mm, particle size 1.7 m) for the Acquity system. For quantitation of Xavone in the biological matrices a mobile phase (methanol 55%: ammonium acetate buVer 0.1 M, pH 5.1, with EDTA 0.27 mM) was used in isocratic mode. The Xow rate was 1 ml/min (Varian) or 0.4 ml/min (Acquity). Quercetin was used as internal standard. The UV detector used here aVorded a limit of quantitation (LOQ) for tricin and apigenin in plasma of 50 and 25 ng/ml, respectively. The LOQ for tricin constitutes a tenth of the value reported by us previously [8] , the precision was < 15%. In the case of some HPLC-UV analyses designed to help characterize metabolites (including those which yielded the chromatograms shown in Figs. 3 and 6) and of HPLC-mass spectrometric analysis, a binary mobile phase system was used (phase A: aqueous ammonium acetate 5 mM; phase B: 5 mM ammonium acetate in methanol), with gradient elution from 75% A/25% B to 10% A/90% B over 45 min (Varian) or 70% A/30% B to 30% A/70% B over 20 min (Acquity).
HPLC-mass spectrometry
Flavones and their metabolites were characterized by HPLC-mass spectrometry using a TurboIon Spray (TIS) source in negative ionization mode. Analyses were performed using an API-2000 mass spectrometer (Applied Biosystems, Warringon, UK) equipped with an Agilent 1100 series sample delivery system. LC separation of Xavones and their metabolites was achieved with the binary mobile phase system, column and Xow rate described above (Varian system). Mass spectrometry conditions were as follows: ion source voltage ¡4,000/¡4,500 V, declustering potential ¡81/¡61 V, focusing potential ¡160/¡230 V, electrode potential ¡12/¡9.5 V, cell entrance potential ¡14/12 V, cell exit potential ¡20/¡20 V, temperature 500°C. IdentiWcation of tricin and apigenin metabolites was by Q1 scan. All mass to charge ratios (m/z) described under
n-Octanol-water partition coeYcient of tricin
Because of the poor water solubility of tricin the noctanol-water partition coeYcient had to be determined indirectly by calculating the equilibrium solubility ratio of tricin in n-octanol to water, in a manner published for apigenin [10] . An excess amount of tricin was suspended in either solvent (10 ml) in screwcapped tubes (in triplicate). Tubes were rotated (room temperature) for 4 days (Rugged Rotator, Glas-Col, Terre Haute, USA), then centrifuged (3,000£g, 20 min). The supernatant was Wltered (0.2 m syringe Wlter, Life Science, Ann Arbor, USA). One volume of Wltrate was mixed with two volumes each of methanol and HPLC mobile phase (see above). The saturation concentration of tricin was quantitated by HPLC as described above.
Statistical evaluation
Flavone levels in the biomatrices and incubation mixtures were statistically compared with each other by one-way ANOVA followed by Tukeys' pairwise comparison.
Results
Flavone levels in mice after dietary intake
Initially the hypothesis was tested that plasma levels of Xavones reach steady state when mice ingest apigenin or tricin for more than 5 days with the diet at 0.2% (dose »300 mg/kg). To that end plasma levels of Xavones were determined in animals which had received Xavones for either 5, 6 or 7 days. Plasma levels of tricin were 0.33-0.45 nmol/ml (with standard deviation between 19 and 24% of the mean), and those of apigenin 0.08-0.11 nmol/ml (with standard deviation between 120 and 182% of the mean). There was no signiWcant diVerence in levels between the three time points, suggesting that Xavone steady-state concentrations were indeed achieved by 5 days. Next Xavone levels achieved after consumption of either tricin or apigenin for 7 days in the plasma, liver or intestinal mucosa were compared. Figure 2 shows representative HPLC chromatograms of plasma preparations. Plasma of control mice (unexposed to Xavones) did not contain substances which co-eluted with apigenin or tricin Each chromatogram is representative of four mice. Quercetin served as internal standard. AU absorbance units. Chromatographic analysis was conducted using the Acquity system in isocratic elution mode, for conditions see Materials and methods. The retention times of tricin and apigenin in spiked samples were 2.84 and 2.83 min, respectively, thus not identical, but very close to each other. On further chromatographic investigation using several conditions allowing increased retention times, the peaks just after the solvent front in b did not co-elute with apigenin conjugates (results not shown). In mice exposed to Xavones plasma levels of tricin were about 4.5-fold higher than those of apigenin (Table 1) . In four out of ten mice on apigenin, plasma concentrations of the Xavone were below the LOQ (25 ng/ml, [9] ), whilst tricin was measurable in all animals, which had received tricin. Consistent with the results observed in the plasma, hepatic and small intestinal levels of tricin exceeded those of apigenin by 33 and 100%, respectively ( Table 1) . The higher tissue recovery of tricin as compared to that of apigenin is noteworthy in the light of the fact that in molar terms the dose of tricin (»0.9 mmol/kg) was 20% smaller than that of apigenin (»1.1 mmol/kg).
Metabolism of apigenin and tricin in liver microsomes
We reasoned that the diVerence between levels of tricin and apigenin observed in mouse plasma and liver was related to diVerential susceptibilities of the two Xavones towards hepatic metabolism. To explore this notion Xavones (50 M) were incubated with murine or human liver microsomes in the presence of UDPGA, and incubates were analyzed for presence of parent Xavone and metabolites. Chromatograms were similar for both compounds, comprising a major peak (retention times »10 min) and two minor peaks (retention times 3-5 min) in each case ( Fig. 3a-d) . The major peaks, which eluted at the retention times of authentic Xavones, aVorded the UV spectra of tricin and apigenin characterized by two absorbance maxima each at 352 nm/266.6 nm and 336.3 nm/265.4 nm, respectively. Formation of the metabolite peaks depended on the presence of UDPGA. UV spectroscopic analysis of these species allows tentative inferences to be made as to the site of metabolic glucuronidation in the Xavone molecule [11] . The spectrum of the tricin conjugate with the retention time of »3 min was characterized by absorbance maxima at 329.6 and 268.6 nm. The hypsochromic shift of the higher absorbance maximum in comparison to the parent tricin suggests glucuronidation in the B-ring, i.e. at the hydroxy in position 4Ј (see Fig. 1 ). The tricin conjugate with retention time »5 min demonstrated absorbance maxima at 352 nm and at 247 nm, and the hypsochromic shift of the lower maximum when compared to tricin intimates glucuronidation of one of the two hydroxy moieties on ring A. In contrast, the UV spectra of the two apigenin metabolites, which both displayed absorbance maxima at 336 nm and 265.1 nm, were too similar to that of parent apigenin to permit inferences to be made as to the site of conjugate attachment. On-line HPLC-mass spectrometric analysis conWrmed the identity of the major peaks as apigenin and tricin with molecular ions of m/z 269 and 329 (all m/z values: [M-H + ] ¡ ions), respectively. The small peaks, which did not separate satisfactorily on HPLC-mass spectrometric analysis, aVorded molecular ions of m/z 505 in the case of incubations with tricin and m/z 445 for apigenin (Fig. 4a, b) , with prominent loss of 176 atomic mass units (glucuronyl), suggestive of mono-glucuronides of either Xavone. Figures 4a and b show the mass spectra of the metabolites observed in human liver microsomes. The results in mouse microsomes were identical to those shown in the Wgure. For this HPLC-MS analysis the Varian chromatographic system was used, which did not separate the two isomeric glucuronides as satisfactorily as the Acquity system shown in Fig. 3 . Thus the mass spectra in Fig. 4a and b are of mixtures of the two isomeric glucuronides. When liver microsomes were replaced with murine or human gut microsomes, extracts of incubates yielded chromatograms very similar to those shown in Fig. 3 for liver (data not shown).
Samples were removed from hepatic microsomal incubates at diVerent time intervals up to 20 (mouse microsomes) or 60 min (human microsomes), and residual Xavones were quantitated. At the end of the incubation period, less than 20% of initial amount of Xavone remained in the incubation medium (Fig. 5a,  b) . Amounts of apigenin left unmetabolized were consistently below those for tricin at each time point in microsomes from either species, suggesting that the rate of metabolic glucuronidation of apigenin was faster than that of tricin. The diVerence was more marked in human than in murine microsomes.
Apigenin has been suggested to undergo NADPHdependent phase I drug metabolism in rat liver microsomes in vitro to a mono-hydroxylated derivative, luteolin (3Ј,4Ј,5,7-tetrahydroxyXavone) [12] . In order to explore whether tricin also undergoes phase I biotransformation, tricin and apigenin were incubated side-by- side with mouse liver microsomes in the presence of NADPH. Figure 6 shows that analysis of extracts of incubates with apigenin furnished a metabolite peak, whilst analysis of extracts of tricin incubates did not reveal signiWcant peaks in addition to that of parent agent. On UV spectroscopic analysis the apigenin Each spectrum is representative of six samples from pooled preparations from three humans. HPLC separation was achieved using the Varian system. The separation of the glucuronide peaks was not as satisfactory as that shown in Fig. 3 349.0 D metabolite showed a high absorbance maximum of 347.0 nm, above that of the equivalent absorbance maximum of apigenin, consistent with this metabolite being luteolin [12] . Unlike apigenin, tricin does not seem to undergo phase I drug metabolism at a measurable rate in mouse liver micosomes.
Next the hypothesis was tested that apigenin or tricin can induce their own metabolic glucuronidation. Liver microsomes from mice, which had ingested dietary Xavone (0.2%) for a week, were incubated with tricin in the presence of UDPGA, and removal of substrate was quantitated. The rate of substrate removal by microsomes from mice, which had received tricin, was 9.6 § 1.3% faster than substrate removal in control microsomes (P < 0.001, n = 4). Similarly, the rate of substrate glucuronidation by microsomes from mice on apigenin exceeded control metabolism by 12.1 § 3.3% (P < 0.002, n = 4). This result suggest that both Xavones weakly induce murine glucuronyl transferase as reXected by tricin glucuronidation.
Metabolism of apigenin and tricin in liver cytosol
Flavones (50 M) were incubated with murine or human liver cytosol in the presence of PAPS, and incubates were analyzed for presence of parent agent and metabolites. Analysis of the cytosol of either species aVorded parent Xavone and metabolite peaks with retention times close to 6 min. Incubates with tricin containing cytosol from humans or mice aVorded one or two metabolites, respectively (Fig. 3e, g ). Analysis of incubates with apigenin aVorded one metabolite (Fig. 3f, h) . Formation of the metabolite peaks depended on the presence of PAPS. The metabolite species derived from tricin with retention time of »5.8 min was characterized by absorbance maxima of 324.4 nm and 268.3 nm, suggesting sulfonation of the hydroxy moiety at position 4Ј. The tricin metabolite peak with retention time »6.1 min gave 349.4 and 244.9 nm, consistent with sulfate attachment at one of the two hydroxy moieties on ring A. The absorbance maxima of the sulfate metabolite of apigenin were very similar to those of parent apigenin confounding structural deductions to be made. When liver cytosol was replaced by intestinal cytosol in the incubations, the chromatograms recorded were very similar to those shown in Fig. 3 for liver cytosol (data not shown) . Characterization of the metabolite peaks by HPLC-mass spectrometry aVorded m/z 409 for extracts of incubates with tricin and m/z 349 for extracts of mixtures with apigenin (Fig. 4c, d) , with prominent loss of 80 atomic mass units (sulfate), consistent with mono-sulfate conjugates. Figure 4c and d shows the mass spectra of the metabolites observed in human liver cytosol, the results in mouse cytosol were identical to those shown in Fig. 4 .
Samples were removed form incubates with liver cytosol at diVerent time intervals up to 60 min, and residual Xavone was quantitated. Overall, the rate of Xavone removal by metabolic sulfonation (Fig. 5c, d ) was much slower than that of glucuronidation (Fig. 5a , b). In murine liver cytosol tricin was metabolically removed more swiftly than apigenin, the diVerence between tricin and apigenin in terms of amount of Xavone left un-metabolized being signiWcant for both time points (Fig. 5c ). In contrast, there was no diVerence in rate of metabolic removal between the two Xavones in human cytosol (Fig. 5d) . The results suggest that in mice the rate of metabolic sulfonation of tricin was faster than that of apigenin. Mouse liver cytosol from mice, which had ingested dietary Xavone (0.2%) for a week, was incubated with tricin in the presence of PAPS, and removal of substrate was quantitated. The rate of tricin removal by sulfonation in cytosol from mice which had ingested Xavones was indistinguishable from the metabolism seen with cytosol from control mice. This result suggests that the two Xavones did not induce sulfotransferase enzymes.
Lipophilicity of tricin
Measurement of the n-octanol-water partition coeYcient calculated from the saturation solubility of tricin in n-octanol and water aVorded log P = 3.24.
Discussion
Flavones are much less abundant in the plant kingdom than the other types of Xavonoids. It is therefore not surprising that little is known about the bioavailability and metabolism of Xavones as compared to other Xavonoids [13] . The work described here explored these areas of Xavone pharmacology for tricin and apigenin. The results show that the steady-state level achieved in the plasma and liver of mice after dietary consumption of either Xavone was higher for tricin than for apigenin, suggesting that tricin is systemically more available than apigenin. For the interpretation of the data presented here it seems useful to note that the dietary dose investigated (»300 mg/kg per day) far exceeds the amount of Xavonoids consumed by humans with the diet, which has been estimated to be between 23 mg and 1.1 g per day [14] . One of the processes, which determine the systemic availability of Xavonoids after oral consumption, is hepatic metabolism. The results of the metabolism experiments in liver preparations in vitro described here suggest that the diVerence in systemic availability may be, at least in part, the corollary of a diVerence between tricin and apigenin in phase II metabolism. In murine and human hepatic microsomes in vitro apigenin underwent more rapid glucuronidation than tricin. In contrast, tricin was more swiftly conjugated with activated sulfate than apigenin in liver from mice, albeit not in liver from humans. Importantly, the rate of Xavone glucuronidation in vitro was considerably faster than that of sulfonation. Extrapolating these Wndings to the in vivo scenario, it is likely that glucuronide formation contributed more prominently than sulfonation to the overall phase II metabolic clearance of either Xavone from the murine organism. Therefore diVerences in glucuronidation rates between tricin and apigenin may have been, at least in part, responsible for the diVerential systemic availability of the Xavones in mice. The diVerence in glucuronidation rate between the two Xavones was also observed in liver microsomes from humans, hinting at the possibility that the corollary of this diVerence for the systemic availability of the two Xavones in mice may also hold for humans. This notion needs of course clinical pharmacological veriWcation. Tricin has not yet been studied in humans, and there is to our knowledge only one report on the metabolism of apigenin in humans, according to which apigenin monoglucurono-and monosulfo-conjugates were recovered from the urine [15] . Our result demonstrating that apigenin underwent NADPH-dependent phase I metabolism to luteolin in mouse liver microsomes at a detectable rate, whilst tricin did not, suggests that this diVerence, if it applies to Xavone biotransformation also in vivo, may have played a role in the superior systemic availability of tricin over apigenin. It remains to be investigated whether hydroxylation contributes indeed to the metabolic clearance of apigenin in vivo. Experiments in the perfused rat liver model suggest that, unlike in liver microsomes in vitro, phase I metabolites of apigenin could not be found in this ex vivo system [12] , intimating the possibility that apigenin hydroxylation may be quantitatively insigniWcant in vivo. It needs to be stressed, that the diVerence in systemic levels between apigenin and tricin after dietary intake may also have been caused by processes unrelated to metabolism, for example by diVerential absorption. It is conceivable that the two methoxy moieties in positions 3Ј and 5Ј of the Xavone scaVold increase the lipophilicity of tricin in comparison with apigenin, thus possibly rendering tricin more easily absorbable than apigenin on physicochemical grounds. Consistent with this notion is the diVerence between the two Xavones in n-octanol water partition coeYcient. The log P value for apigenin has previously been calculated as 2.87 [10] , whilst we established 3.24 as the log P for tricin. On the basis of experiments in hepatoma cells in vitro apigenin has been suggested to induce metabolic glucuronidation [16] . Consistent with this observation both Xavones were found here to be weak inducers of the glucuronyl transferase-catalyzed metabolism of tricin in mice in vivo.
We characterize here for the Wrst time tricin sulfate and tricin glucuronide as tricin metabolites in murine and human liver preparations. Apigenin and tricin possess three hydroxy moieties, which are potentially susceptible to conjugative metabolism. Our analytical method did not allow localization of the exact position of glucuronyl or sulfate attachment. Previously three monoglucuronides of apigenin have been identiWed in incubations with rat liver microsomes, again without exact deWnition of positional attachment of the glucuronyl moiety [12] . One of these metabolites was quantitatively prevalent. The UV spectroscopic analysis of the tricin conjugates described above suggests that tricin is predominantly glucuronidated at one of the two hydroxy moieties in ring A. The fact that apigenin was glucuronidated in vitro faster than tricin may be related to the presence of two methoxy moieties in positions 3Ј and 5Ј in tricin, which are absent from apigenin. These methoxy groups may have somewhat hindered the interaction of the tricin molecule with glucuronyl transferase. Levels of tricin exceeded those of apigenin also in the small intestinal tract, and it remains to be seen, whether apigenin will accordingly be less eYcacious than tricin in the Apc Min mouse model, in which tricin interfered signiWcantly with small intestinal adenoma development [4] . Flavone metabolites could not be detected in the plasma or liver or gastro-intestinal tissues of mice, which had received dietary Xavones, whilst preliminary inspection of the urine of mice exposed to Xavones suggests the presence of three conjugate metabolites for apigenin and two for tricin (results not shown). The Wndings presented here need to be interpreded side-by-side with some other results, which may allow a tentative comparison of their pharmacological proWle. Both apigenin and tricin lack mutagenic properties, as reXected by a variety of tests [17, 18] . Their ability to inhibit cancer cell growth has been determined in human breast cancer-derived MDA MB 468 and in human colon cancer-derived HCA-7 and SW 480 cells. MDA MB 468 cells were more sensitive to the growthretarding properties of tricin than those of apigenin, with IC 50 values of 0.6 and 33 M for tricin and apigenin, respectively [19, 20] . Colon cancer cells were more sensitive to apigenin, as reXected by IC 50 values of >40 and 18 M for tricin and apigenin, respectively, in HCA-7 cells [3] and of >40 and 23 M in SW 480 cells (M. Al-Fayez, H. Cai, W.P. Steward and A.J. Gescher, unpublished data). It is conceivable that Xavonoid conjugate metabolites contribute to the pharmacological activity ascribed to the parent Xavonoid. A good example is quercetin 3-O-glucuronide, which has been shown to inhibit c-Jun terminal kinase (JNK) activity and binding to DNA of transcription factor activator protein-1 (AP-1) in vascular smooth muscle cells [21] .
Overall the results discussed here are germane to the planning of clinical trials, in which the hypothesis is tested that COX-modulatory Xavonoids can be used in lieu of non-steroidal anti-inXammatory drugs to interfere with adenoma recurrence and/or colorectal cancer development in humans. The type of data presented here contributes to the knowledge base, which will enable prioritization of Xavonoid analogs for advancement to the stage of clinic evaluation. The comparison of tricin and apigenin hints at a potential pharmacokinetic advantage, which tricin may oVer over apigenin in terms of superior systemic and gastro-intestinal availability.
